These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 23302941)

  • 1. [Current status of combination therapies of angiogenesis inhibitors: vascular normalization activity of a novel angiogenesis inhibitor E7820].
    Semba T
    Nihon Yakurigaku Zasshi; 2013 Jan; 141(1):4-8. PubMed ID: 23302941
    [No Abstract]   [Full Text] [Related]  

  • 2. An angiogenesis inhibitor E7820 shows broad-spectrum tumor growth inhibition in a xenograft model: possible value of integrin alpha2 on platelets as a biological marker.
    Semba T; Funahashi Y; Ono N; Yamamoto Y; Sugi NH; Asada M; Yoshimatsu K; Wakabayashi T
    Clin Cancer Res; 2004 Feb; 10(4):1430-8. PubMed ID: 14977846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium.
    Funahashi Y; Sugi NH; Semba T; Yamamoto Y; Hamaoka S; Tsukahara-Tamai N; Ozawa Y; Tsuruoka A; Nara K; Takahashi K; Okabe T; Kamata J; Owa T; Ueda N; Haneda T; Yonaga M; Yoshimatsu K; Wakabayashi T
    Cancer Res; 2002 Nov; 62(21):6116-23. PubMed ID: 12414636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors.
    Milojkovic Kerklaan B; Slater S; Flynn M; Greystoke A; Witteveen PO; Megui-Roelvink M; de Vos F; Dean E; Reyderman L; Ottesen L; Ranson M; Lolkema MP; Plummer R; Kristeleit R; Evans TR; Schellens JH
    Invest New Drugs; 2016 Jun; 34(3):329-37. PubMed ID: 27039386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies.
    Mita M; Kelly KR; Mita A; Ricart AD; Romero O; Tolcher A; Hook L; Okereke C; Krivelevich I; Rossignol DP; Giles FJ; Rowinsky EK; Takimoto C
    Clin Cancer Res; 2011 Jan; 17(1):193-200. PubMed ID: 21208908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of α2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studies.
    Keizer RJ; Funahashi Y; Semba T; Wanders J; Beijnen JH; Schellens JH; Huitema AD
    AAPS J; 2011 Jun; 13(2):230-9. PubMed ID: 21387147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of chemotherapeutic efficacy by vascular disrupting agents: optimizing the sequence and schedule.
    Wang ES; Pili R; Seshadri M
    J Clin Oncol; 2012 Mar; 30(7):760-1; author reply 761-3. PubMed ID: 22291088
    [No Abstract]   [Full Text] [Related]  

  • 8. The small-molecule protein ligand interface stabiliser E7820 induces differential cell line specific responses of integrin α2 expression.
    Hülskamp MD; Kronenberg D; Stange R
    BMC Cancer; 2021 May; 21(1):571. PubMed ID: 34006252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Progress of research and development of MAPK pathway inhibitors].
    Ishii N
    Nihon Yakurigaku Zasshi; 2013 Jan; 141(1):15-21. PubMed ID: 23302943
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-angiogenic therapies in metastatic breast cancer-an unfulfilled dream.
    Buzdar AU
    Lancet Oncol; 2011 Apr; 12(4):316-8. PubMed ID: 21429798
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical development of vascular disrupting agents: what lessons can we learn from ASA404?
    Lorusso PM; Boerner SA; Hunsberger S
    J Clin Oncol; 2011 Aug; 29(22):2952-5. PubMed ID: 21709201
    [No Abstract]   [Full Text] [Related]  

  • 12. Anticancer therapy with angiogenesis inhibitors.
    Ghilardi C; Bani MR; Giavazzi R
    Tumori; 2001; 87(6):S14-6. PubMed ID: 11989610
    [No Abstract]   [Full Text] [Related]  

  • 13. Angiogenesis inhibition in solid tumors.
    Rosen LS
    Cancer J; 2001; 7 Suppl 3():S120-8. PubMed ID: 11779082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
    Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE
    Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Targeted therapies and their indications in solid neoplasias].
    Dreyer C; Raymond E; Faivre S
    Rev Med Interne; 2009 May; 30(5):416-24. PubMed ID: 19299048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic therapy for cancer: current and emerging concepts.
    Jain RK
    Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):7-16. PubMed ID: 15934498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VEGF-targeted therapy: mechanisms of anti-tumour activity.
    Ellis LM; Hicklin DJ
    Nat Rev Cancer; 2008 Aug; 8(8):579-91. PubMed ID: 18596824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
    Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
    Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
    Wang D; Tang F; Wang S; Jiang Z; Zhang L
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.